Open AccessBendamustine treatment of Chinese patients with relapsed indolent non-Hodgkin lymphoma: a multicenter, open-label, single-arm, phase 3 study
Author(s) -
Yuankai Shi,
Xin Hong,
Jianliang Yang,
Wei Xu,
Huiqiang Huang,
Xiubin Xiao,
Jun Zhu,
Daobin Zhou,
Xiaohong Han,
Jianqiu Wu,
Mingzhi Zhang,
Jie Jin,
Xiaoyan Ke,
Wei Li,
Depei Wu,
Shenmiao Yang,
Xin Du,
Yongyi Jia,
Ai-Chun Liu,
DaiHong Liu,
Zhi-Xiang Shen,
Liansheng Zhang,
Leonard P. James,
Edward T. Hellriegel
Publication year - 2021
Publication title -
chinese medical journal/chinese medical journal
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.537
H-Index - 63
eISSN - 2542-5641
pISSN - 0366-6999
DOI - 10.1097/cm9.0000000000001463
Subject(s) - bendamustine , medicine , clinical endpoint , non hodgkin's lymphoma , rituximab , phases of clinical research , surgery , lymphoma , clinical trial
Bendamustine was approved in China on May 26th, 2019 by the National Medical Product Administration for the treatment of indolent B-cell non-Hodgkin lymphoma (NHL). The current study was the registration trial and the first reported evaluation of the efficacy, safety, and pharmacokinetics of bendamustine in Chinese adult patients with indolent B-cell NHL following relapse after chemotherapy and rituximab treatment.